Company / Capital Expenditures
Corcept Therapeutics Incorporated Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$211.0K
FY2025
5-year range
$139.0K / $2.2M
FY2021-FY2025
Trend
-90.3%
vs FY2024
Sector context
#158 of 194
Health Care
What the data says
Corcept Therapeutics Incorporated's capital expenditures of $211,000 is lower than 81% of companies in the Health Care sector (FY2025). Capital Expenditures has fluctuated over the past 10 years, ranging from $139,000 in FY2023 to $2M in FY2024.
Based on SEC 10-K filings.
$211,000 in FY2025 with a 5-year CAGR of -6.7%.
Improved from $139,000 to $211,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -44.6%
- 5-Year CAGR
- -6.7%
- 10-Year CAGR
- -
Sector benchmark
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -6.7%, indicating a declining trend.
- In FY2025, capital expenditures decreased 90.3% year-over-year.
- Ranks #158 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 3.44 (safe zone, above 2.9 threshold)
- Strong profit margin: 20.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $211.0K | -90.3% |
| FY2024 | $2.2M | +1462.6% |
| FY2023 | $139.0K | -88.8% |
| FY2022 | $1.2M | +13.8% |
| FY2021 | $1.1M | +265.1% |
| FY2020 | $298.0K | -28.9% |
| FY2019 | $419.0K | +116.0% |
| FY2018 | $194.0K | -53.7% |
| FY2017 | $419.0K | +140.8% |
| FY2016 | $174.0K | +923.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026